Therapeutic Proteins And Oral Vaccines Market Size to Exceed USD 497.8 Mn by 2032

The Therapeutic Proteins And Oral Vaccines Market, estimated at USD 288.6 Mn in 2025, is expected to exhibit a CAGR of 8.1% and reach USD 497.8 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Key market players are focusing on adopting growth strategies such as signing collaboration agreements with market players, which will drive the global therapeutic proteins and oral vaccines market. For instance, In July 2019, Vaxart, Inc., a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that it had entered into a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen), a pharmaceutical company to evaluate Vaxart’s proprietary oral vaccine platform for the Janssen universal influenza vaccine program.

Global Therapeutic Proteins and Oral Vaccines Market– Impact of Coronavirus (COVID-19) Pandemic

The increasing prevalence of COVID-19 has caused production factories to shutdown in almost all sectors, and also affected the supply of raw materials and active pharmaceutical ingredients (API) of manufacturing companies across the globe.

Moreover, various guidelines have been implemented by regulatory authorities for manufacturing of active pharmaceutical ingredients and pharmaceutical products to avoid the spread of COVID-19 and also to reduce the contamination of active pharmaceutical ingredients during the manufacturing process of pharmaceutical products such as vaccines, tablets, etc.

According to the U.S. Food Drug and Administration’s report of June 2020, owing to the COVID-19 public health emergency, drug manufacturers are required to abide by the following current good manufacturing practice (CGMP) regulations and recommendations regarding restriction of sick employees from production areas. 1) Any employee or worker in a production unit should be medically evaluated for infectious diseases such as COVID-19. 2) If any of individual is exhibiting COVID-19 symptoms, they shall be restricted from entering the production house premises of the company to prevent contamination of drugs and active pharmaceutical ingredients (API).

Moreover, in April 2020, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) published guidelines on exceptional GMP flexibilities for medicine manufacturers during the coronavirus (COVID-19) outbreak. The guidelines are as follows.

• Re-testing of raw materials and tested raw materials should have suppliers certification of analysis (COA).
• Raw materials or products can be transported from one manufacturing site to another manufacturing site after the completion of a QC test and batch certification and products should not be placed in the market until certified by a qualified person in the company.

Global Therapeutic Proteins and Oral Vaccines Market: Key Developments

On March 21 2023, NVIDIA, a software company, announced an expanded set of generative Artificial Intelligence (AI) cloud services for customizing AI foundation models to accelerate the creation of new proteins and therapeutics, as well as research in the fields of genomics, chemistry, biology and molecular dynamics.

On July 17 2023, Lonza, a contract manufacturing company  launched the TheraPRO CHO Media System, a new cell culture platform that simplifies processes and optimizes productivity and protein quality when used with GS-CHO cell lines. The launch supports pharmaceutical and biotechnology companies manufacturing therapeutic proteins to further improve product quality while streamlining time-to-market.

In July 2021, Eli Lilly and Company, a pharmaceutical company, announced the acquisition of Protomer Technologies, a private biotech company. Protomer's proprietary peptide- and protein-engineering platform is used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity.

In June 2020, Regeneron Pharmaceuticals, Inc., a leading biotechnology company, and Intellia Therapeutics, Inc., a leading genome editing company, announced an expansion of their existing collaboration to provide Regeneron Pharmaceticals, Inc., with rights to develop products for additional in vivo CRISPR/Cas9-based therapeutic targets and for the companies to jointly develop potential products for the treatment of hemophilia A and B.

Browse 36 Market Data Tables and 26 Figures spread through 180 Pages and in-depth TOC on “Global Therapeutic Proteins and Oral Vaccines Market”- Forecast to 2030, Global Therapeutic Proteins and Oral Vaccines Market, By Drug Class [Therapeutic Proteins  (Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, and Others), Oral Vaccines (Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, and Others)], By Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),  and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/therapeutic-proteins-and-oral-vaccines-market-4396

Key Takeaways of the Global Therapeutic Proteins and Oral Vaccines Market:

• The global therapeutic proteins and oral vaccines market is expected to exhibit a CAGR of 8.1% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global therapeutic proteins and oral vaccines market.
• Among drug class, the therapeutic proteins segment is expected to hold a dominant position in the global therapeutic proteins and oral vaccines market during the forecast period, and this is attributed to increasing research and development by market players. For instance, in December 2021, Dyadic International, Inc., a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of protein based vaccines and therapeutics, announced that it had entered into a research, license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The Agreement was facilitated by Johnson & Johnson Innovation.
• Among region, North America is expected to be the dominant region in the global therapeutic proteins and oral vaccines market, owing to the government organizations providing services in the region. For instance, in August 2022, the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) will begin its annual distribution of RABORAL V-RG, an oral rabies vaccine (ORV) bait, in select areas in the eastern U.S. to prevent the spread of raccoon rabies into America’s heartland.
• Major players operating in the global therapeutic proteins and oral vaccines market are Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson and Johnson, Merck & Co.Inc., Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd., and Lumen Bioscience, Inc.